Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Inovio Pharmaceuticals to related companies based on the strength of its dividends, valuation, risk, institutional ownership, analyst recommendations, profitability and earnings.
Insider and Institutional Ownership
26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Inovio Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inovio Pharmaceuticals | N/A | -28,886.30% | -75.67% |
| Inovio Pharmaceuticals Competitors | -12,224.09% | -202.33% | -31.23% |
Valuation and Earnings
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Inovio Pharmaceuticals | $60,000.00 | -$84.95 million | -2.65 |
| Inovio Pharmaceuticals Competitors | $699.91 million | $8.25 million | -18.80 |
Inovio Pharmaceuticals’ rivals have higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Inovio Pharmaceuticals and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inovio Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
| Inovio Pharmaceuticals Competitors | 9916 | 15312 | 45656 | 1602 | 2.54 |
Inovio Pharmaceuticals presently has a consensus price target of $6.33, indicating a potential upside of 342.89%. As a group, “Biotechnology” companies have a potential upside of 126.23%. Given Inovio Pharmaceuticals’ higher possible upside, research analysts clearly believe Inovio Pharmaceuticals is more favorable than its rivals.
Volatility and Risk
Inovio Pharmaceuticals has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals’ rivals have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.
Summary
Inovio Pharmaceuticals rivals beat Inovio Pharmaceuticals on 8 of the 12 factors compared.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a biotechnology company developing DNA medicines, including treatments intended to stimulate the body’s immune response to cancers and infectious diseases. Its research has focused on therapeutic and preventive applications, with candidates targeting conditions such as human papillomavirus (HPV)-related disease. The company’s technology uses synthetic DNA plasmids designed to prompt cells to produce targeted antigens. Inovio has also developed its CELLECTRA platform, which uses electroporation to help deliver DNA medicines into cells.
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
